ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

The US Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer. The agency sent a warning letter ...

Fred Hutch Cancer Center researchers are seeking better ways to prevent, detect and treat bladder cancer. We are also working to better understand the factors that affect each person’s risk for this ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

ImmunityBio has secured a critical regulatory milestone for its lead oncology drug, Anktiva, providing a significant counterpoint to recent market volatility. An independent data monitoring board has ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

ImmunityBio Inc.’s shares plunged after the biotechnology company and its billionaire Executive Chairman Patrick Soon-Shiong ...

Federal health officials posted a warning about misleading statements by biotech billionaire Dr. Patrick Soon-Shiong about ...

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically ...